NCT04185363Phase 3Completed

An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

Study sponsor: Mirum Pharmaceuticals, Inc. · MIRM

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-04-23Actual
Enrollment · participants84Actual
Source updated2026-06-23Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of Treatment Emergent Adverse Events (TEAEs) during the study. After: Measure: Mean Change From Baseline Over Time in the Average Morning ItchRO(Obs) Severity Score.

Actual enrollment decreased by 6 participants

Before: 90 participants (actual). After: 84 participants (actual).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview